Whole tumor cell vaccine with irradiated S180 cells as adjuvant

Summary Whole tumor cell vaccines have been widely studied and remain promising cancer immunotherapies. In the present study, we discovered that vaccination with irradiated mouse sarcoma S180 tumor cells stimulated robust antitumor immunity to autologous tumor cells in both syngenic and allogenic mi...

Full description

Saved in:
Bibliographic Details
Published in:Vaccine 2009-01, Vol.27 (4), p.558-564
Main Authors: Li, Jinhua, King, Ada V, Stickel, Sara L, Burgin, Kelly E, Zhang, Xinhai, Wagner, Thomas E, Wei, Yanzhang
Format: Article
Language:English
Subjects:
Adjuvant
Adjuvants, Immunologic
Allergy and Immunology
Animals
Antigens
Applied microbiology
Biological and medical sciences
Cancer
Cancer Vaccines - genetics
Cancer Vaccines - immunology
Cancer Vaccines - therapeutic use
Cell Line, Tumor - radiation effects
Cells
Female
Fundamental and applied biological sciences. Psychology
Immunotherapy
Immunotherapy - methods
Killer Cells, Natural - immunology
Laboratory animals
Medical sciences
Mice
Mice, Inbred BALB C
Mice, Nude
Microbiology
Neoplasms - genetics
Neoplasms - immunology
S180
Sarcoma
Sarcoma 180 - genetics
Sarcoma 180 - immunology
TC-1
Tumors
Vaccines
Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies (general aspects)
Vaccines, Synthetic - immunology
Whole cell vaccine
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Summary Whole tumor cell vaccines have been widely studied and remain promising cancer immunotherapies. In the present study, we discovered that vaccination with irradiated mouse sarcoma S180 tumor cells stimulated robust antitumor immunity to autologous tumor cells in both syngenic and allogenic mice. The antitumor activity requires both T and B cells, but not NK cells. When a mouse lung carcinoma (TC-1) whole tumor cell vaccine was combined with the S180 vaccine, the antitumor immunity against live TC-1 tumor cells is significantly enhanced compared to a TC-1 whole cell vaccine alone. This antitumor immunity not only prevents live tumor challenge but also eradicates existing tumor cells. A similar phenomenon was also observed when S180 vaccine was combined with LL2 Lewis lung carcinoma tumor cells. Therefore, S180 vaccine may serve as an adjuvant for other whole tumor cell vaccines.
ISSN:0264-410X
1873-2518
DOI:10.1016/j.vaccine.2008.11.014